Published in PLoS One on December 14, 2012
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. Mol Pharmacol (2013) 1.14
G Protein-Coupled Receptor Heteromers. Annu Rev Pharmacol Toxicol (2015) 0.88
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol (2015) 0.85
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol (2014) 0.84
Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function. Front Pharmacol (2014) 0.82
PnPP-19, a spider toxin peptide, induces peripheral antinociception through opioid and cannabinoid receptors and inhibition of neutral endopeptidase. Br J Pharmacol (2016) 0.80
Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80
In vivo opioid receptor heteromerization: where do we stand? Br J Pharmacol (2014) 0.80
Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev (2016) 0.80
Contribution of heteromerization to G protein-coupled receptor function. Curr Opin Pharmacol (2016) 0.76
A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems. J Venom Anim Toxins Incl Trop Dis (2016) 0.75
Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell (2016) 0.75
Effects of Centrally Administered Endocannabinoids and Opioids on Orofacial Pain Perception in Rats. Br J Pharmacol (2017) 0.75
Intra-accumbal Cannabinoid Agonist Attenuated Reinstatement but not Extinction Period of Morphine-Induced Conditioned Place Preference; Evidence for Different Characteristics of Extinction Period and Reinstatement. Neurochem Res (2017) 0.75
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods (1994) 23.05
An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain (1992) 9.17
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol (1980) 6.82
The evidence for pharmacological treatment of neuropathic pain. Pain (2010) 4.35
Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet (2000) 3.10
Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci U S A (1998) 3.07
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci (2000) 2.90
Cannabinoid receptors and pain. Prog Neurobiol (2001) 2.48
Treatment of neuropathic pain: an overview of recent guidelines. Am J Med (2009) 2.43
Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation. Neuron (2011) 2.42
Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A (2005) 2.29
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci (2006) 2.02
Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol (2005) 1.96
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 1.93
Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther (2006) 1.93
Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci (2007) 1.91
Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal (2010) 1.90
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci (2006) 1.80
Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci (2001) 1.67
Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci (2001) 1.66
Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. Pain (2000) 1.65
Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain (2006) 1.61
Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci (1994) 1.58
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci (1999) 1.49
The [35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci (2003) 1.47
The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience (2006) 1.44
Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci (2004) 1.42
Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther (2007) 1.39
Receptor heteromerization and drug discovery. Trends Pharmacol Sci (2010) 1.37
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem (2006) 1.37
Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience (2005) 1.30
Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol (2006) 1.27
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther (2007) 1.26
Segmental spinal nerve ligation model of neuropathic pain. Methods Mol Med (2004) 1.24
Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) (2002) 1.23
Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain (2009) 1.23
Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci (1995) 1.23
Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain (2003) 1.22
Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med (2010) 1.22
Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol Biochem Behav (2008) 1.19
Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain (2004) 1.18
AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J (2011) 1.18
Anti-allodynic effects of peripheral delta opioid receptors in neuropathic pain. Pain (2006) 1.17
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.17
Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry (2009) 1.16
Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br J Pharmacol (2007) 1.15
The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex (2008) 1.15
Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann Neurol (2003) 1.12
Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry (2004) 1.12
Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther (2004) 1.11
Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. Neuroscience (2004) 1.10
Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Eur J Pain (2006) 1.10
Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res (1999) 1.06
Central mechanisms of experimental and chronic neuropathic pain: findings from functional imaging studies. Cell Mol Life Sci (2009) 1.05
Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death Dis (2011) 1.03
Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience (2002) 1.03
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Experimental neuropathy in mice is associated with delayed behavioral changes related to anxiety and depression. Anesth Analg (2007) 1.00
Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons. Mol Pharmacol (2011) 1.00
Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) (2005) 0.99
Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience (2003) 0.98
Nociceptive behavior in animal models for peripheral neuropathy: spinal and supraspinal mechanisms. Prog Neurobiol (2008) 0.97
Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry (2005) 0.97
Chronic pain-induced emotional dysfunction is associated with astrogliosis due to cortical delta-opioid receptor dysfunction. J Neurochem (2006) 0.96
Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res (1998) 0.96
The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behav Brain Res (2011) 0.94
Trafficking of central opioid receptors and descending pain inhibition. Mol Pain (2007) 0.92
Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal gray. Neuroscience (2012) 0.91
G protein-coupled receptor heteromers as new targets for drug development. Prog Mol Biol Transl Sci (2010) 0.91
Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One (2012) 0.91
Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets (2010) 0.90
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol (2007) 0.90
Bilateral and differential changes in spinal mu, delta and kappa opioid binding in rats with a painful, unilateral neuropathy. Pain (1991) 0.90
Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J Neurotrauma (2011) 0.88
Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharmacol (2003) 0.86
Effects of peripheral nerve injury on delta opioid receptor (DOR) immunoreactivity in the rat spinal cord. Neurosci Lett (2004) 0.86
Immunocytochemical localization of delta opioid receptors in mouse brain. J Chem Neuroanat (1995) 0.86
Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur J Pharmacol (2006) 0.86
Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. Eur J Neurosci (2003) 0.85
Measurement of agonist-stimulated [35S]GTP gamma S binding to cell membranes. Methods Mol Biol (1999) 0.84
Effects of sciatic nerve injuries on delta -opioid receptor and substance P immunoreactivities in the superficial dorsal horn of the rat. Eur J Pain (1999) 0.83
Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases. PLoS One (2011) 0.83
Behavioral and anatomical characterization of the bilateral sciatic nerve chronic constriction (bCCI) injury: correlation of anatomic changes and responses to cold stimuli. Mol Pain (2010) 0.82
Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice. Eur J Neurosci (2005) 0.82
Delta opioid receptor-mediated analgesia is not altered in preprotachykinin A knockout mice. Eur J Neurosci (2010) 0.82
Regulation of opioid binding sites in the superficial dorsal horn of the rat spinal cord following loose ligation of the sciatic nerve: comparison with sciatic nerve section and lumbar dorsal rhizotomy. Neuroscience (1992) 0.81
Effects of peripheral nerve ligation on expression of mu-opioid receptor in sensory ganglion neurons: an immunohistochemical study in dorsal root and nodose ganglion neurons of the rat. Neurosci Lett (1996) 0.81
Influences of surgical decompression on the dorsal horn after chronic constriction injury: changes in peptidergic and delta-opioid receptor (+) nerve terminals. Neuroscience (2008) 0.81
Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain (2007) 0.81
Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. Brain Res (2010) 0.79
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 1.93
Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal (2010) 1.90
Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J (2007) 1.89
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A (2007) 1.70
The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci (2007) 1.68
Systems approach to explore components and interactions in the presynapse. Proteomics (2009) 1.61
Morphine administration alters the profile of hippocampal postsynaptic density-associated proteins: a proteomics study focusing on endocytic proteins. Mol Cell Proteomics (2006) 1.43
Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A (2008) 1.42
Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J (2008) 1.40
Receptor heteromerization and drug discovery. Trends Pharmacol Sci (2010) 1.37
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem (2006) 1.37
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A (2013) 1.34
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem (2005) 1.32
Exploring a role for heteromerization in GPCR signalling specificity. Biochem J (2011) 1.31
Multiple actions of spinophilin regulate mu opioid receptor function. Neuron (2008) 1.30
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 1.28
Opioid receptor oligomerization. Detection and functional characterization of interacting receptors. Methods Mol Med (2003) 1.28
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Novel endogenous peptide agonists of cannabinoid receptors. FASEB J (2009) 1.25
The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. J Biol Chem (2005) 1.25
AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J (2011) 1.18
An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. ScientificWorldJournal (2007) 1.18
Oligomerization of opioid receptors. Methods (2002) 1.17
Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res Mol Brain Res (2005) 1.14
Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct Funct (2010) 1.13
Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J Hepatol (2013) 1.12
Neuropeptide processing profile in mice lacking prohormone convertase-1. Biochemistry (2005) 1.09
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Grand opening of structure-guided design for novel opioids. Trends Pharmacol Sci (2012) 1.04
Obesity and diabetes in transgenic mice expressing proSAAS. J Endocrinol (2004) 1.04
Estrogen receptor (ER)beta isoforms rather than ERalpha regulate corticotropin-releasing hormone promoter activity through an alternate pathway. J Neurosci (2004) 1.04
Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One (2012) 1.03
Interactions between delta opioid receptors and alpha-adrenoceptors. Clin Exp Pharmacol Physiol (2004) 1.02
Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J (2006) 1.02
Inquiry learning. Integrating content detail and critical reasoning by peer review. Science (2008) 1.02
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons. Mol Pharmacol (2011) 1.00
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation. Neuropsychopharmacology (2009) 0.99
Hemoglobin-derived peptides as novel type of bioactive signaling molecules. AAPS J (2010) 0.97
The propeptide precursor proSAAS is involved in fetal neuropeptide processing and body weight regulation. J Neurochem (2010) 0.96
Neuroproteomics of the synapse and drug addiction. J Pharmacol Exp Ther (2006) 0.96
Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann N Y Acad Sci (2009) 0.96
Peptidomics of Cpefat/fat mouse hypothalamus and striatum: effect of chronic morphine administration. J Mol Neurosci (2006) 0.94
Opioid receptor heteromers in analgesia. Expert Rev Mol Med (2012) 0.94
Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem (2003) 0.94
Processing of proSAAS in neuroendocrine cell lines. Biochem J (2002) 0.93
Teaching resources. Cell signaling systems: a course for graduate students. Sci STKE (2005) 0.93
Structural biology: How opioid drugs bind to receptors. Nature (2012) 0.92
Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One (2012) 0.91
Teaching resources. Using web-based discussion forums as a model of the peer-review process and a tool for assessment. Sci Signal (2008) 0.91
Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. J Med Chem (2008) 0.90
Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem (2011) 0.90
Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen (2008) 0.89
Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis. PLoS One (2011) 0.88
GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding. Proc Natl Acad Sci U S A (2013) 0.87
Embryonic gene expression and pro-protein processing of proSAAS during rodent development. J Neurochem (2005) 0.86
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem (2008) 0.86
The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med (2006) 0.86
Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 0.85
Quantification of VGF- and pro-SAAS-derived peptides in endocrine tissues and the brain, and their regulation by diet and cold stress. Brain Res (2006) 0.84
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol (2014) 0.84
Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol (2014) 0.83
Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state. Addict Biol (2011) 0.83
Quantitative neuroproteomics of the synapse. Methods Mol Biol (2010) 0.82
Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal (2005) 0.82
G-protein-coupled heteromers: regulation in disease. Methods Enzymol (2013) 0.80
Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80
Endothelin converting enzyme-2: a processing enzyme involved in the generation of novel neuropeptides. Protein Pept Lett (2004) 0.80
Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord. J Neurochem (2011) 0.79
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mt Sinai J Med (2010) 0.79
Use of proteomics for the identification of novel drug targets in brain diseases. J Neurochem (2007) 0.79
Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice. J Pharmacol Exp Ther (2013) 0.79
Escorts take the lead molecular chaperones as therapeutic targets. Prog Mol Biol Transl Sci (2010) 0.79
An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure. Neuropsychopharmacology (2013) 0.79
Possible involvement of β-endorphin in a loss of the coordinated balance of μ-opioid receptors trafficking processes by fentanyl. Synapse (2011) 0.77
Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay. J Biol Chem (2010) 0.77
A role for transmembrane domains V and VI in ligand binding and maturation of the angiotensin II AT1 receptor. Biol Chem (2006) 0.77